Ignite Creation Date:
2025-12-25 @ 2:19 AM
Ignite Modification Date:
2025-12-29 @ 9:25 AM
Study NCT ID:
NCT06363734
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-09
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-09
First Submit QC Date:
None
Study First Post Date:
2024-04-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-14
Last Update Post Date:
2024-04-16
Last Update Post Date Type:
ACTUAL